News for Plus Therapeutics, Inc. (PSTV)

Plus Therapeutics (PSTV) recently shared promising data on its leading drug, REYOBIQ, at the Nuclear Medicine and Neurooncology Conference held from May 9-10, 2

Multiple long-term LM survivors in those patients receiving multiple doses of REYOBIQ RNA sequencing data show early tumor apoptosis and activation of innate i

In a recent development, D. Boral Capital has adjusted its rating on Plus Therapeutics (PSTV) from 'Buy' to 'Hold'. The change in analyst sentiment was announce

D. Boral Capital has revised its rating for Plus Therapeutics (PSTV), moving from a Buy to a Hold, after the company unveiled its decision to execute a reverse

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiat...

Plus Therapeutics, Inc. (PSTV) has announced the appointment of Kyle Guse to its Board of Directors. Guse will take on the role of chair of the Audit Committee

HOUSTON, April 23, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. ( PSTV) (the ”œCompany”), a clinical-stage pharmaceutical company developing targeted r

Plus Therapeutics (PSTV) achieved a 75% clinical benefit rate through neuroimaging in its Phase 1 ReSPECT-LM trial for REYOBIQâ„¢. No dose-limiting toxi

Summary: Plus Therapeutics (PSTV) is offering 1.57 billion shares to current stockholders. Analysts provide a positive outlook with potential upside exce

Cash and Investments Balance: $3.6 million as of December 31, 2024, compared to $8.6 million at December 31, 2023.Grant Revenue: $5.8 million in 2024, up from

Mar 27, 2025 / 09:00PM GMTOperator Good afternoon, ladies and gentlemen. Welcome to Plus Therapeutics fourth quarter and full-year 2024 results conference call.

Plus Therapeutics' Q4 2024 earnings reveal progress with REYOBIQ nearing FDA approval & CNSide's 2025 launch. Key hires & funding bolster milestones.

Plus Therapeutics, Inc. (NASDAQ:PSTV) Q4 2024 Earnings Conference Call March 27, 2025 5:00 PM ETCompany ParticipantsMarc Hedrick - President and CEOAndrew...

The recent $15 million financing accelerates development of REYOBIQâ„¢ and launch of CNSideâ„¢ HOUSTON, March 27, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics

Plus (PSTV) delivered earnings and revenue surprises of -31.37% and 6.49%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

New Jersey-based Greenland Acquisition Corp (GTEC) is up over 79 percent in Thursday's pre-market trading. The following are some of the other stocks making big moves in Thursday's pre-market trading.

March 11, 2025 (Investorideas.com Newswire) Investorideas.com (www.investorideas.com), a go-to platform for big investing ideas for stock traders, including bio...

Shares of Ouster, Inc. OUST rose sharply in today's pre-market trading after the company reported better-than-expected fourth-quarter financial results. Ouster...

**media[570655]**